Global CDK 4/6 Inhibitor Drugs Market Outlook 2023-2035: A USD 66.63 Billion Market by 2035, Up From USD 9.03 Billion in 2022
April 26, 2024 04:15 ET
|
Research and Markets
Dublin, April 26, 2024 (GLOBE NEWSWIRE) -- The "Global CDK 4/6 Inhibitor Drugs Market Outlook 2023-2035" report has been added to ResearchAndMarkets.com's offering.The global CDK 4/6 inhibitor...
Sermonix Pharmaceuticals Shares Encore ELAINE-2 Poster Presentation at 2023 Metastatic Breast Cancer Research Conference
September 05, 2023 09:00 ET
|
Sermonix Pharmaceuticals Inc.
COLUMBUS, Ohio, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company developing innovative therapeutics to specifically treat metastatic...
Sermonix Pharmaceuticals to Share Longer Patient Follow-up Results for ELAINE-2 in Poster Presentation at ASCO 2023
May 25, 2023 17:00 ET
|
Sermonix Pharmaceuticals Inc.
COLUMBUS, Ohio, May 25, 2023 (GLOBE NEWSWIRE) -- Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company developing innovative therapeutics to specifically treat metastatic breast...
Chemotherapy Drugs Market Insights, Competitive Landscape, and Market Forecasts, 2027
April 13, 2023 10:18 ET
|
Research and Markets
Dublin, April 13, 2023 (GLOBE NEWSWIRE) -- The "Chemotherapy Drugs - Market Insights, Competitive Landscape, and Market Forecast - 2027" drug pipelines has been added to ResearchAndMarkets.com's...
Sermonix Pharmaceuticals Announces Initiation of Phase 3 ELAINE-3 Study of Lasofoxifene Plus Abemaciclib in Pre- and Post-Menopausal Patients with Locally Advanced or Metastatic ER+/HER2- Breast Cancer with an ESR1 Mutation as Detected by Guardant Health’s Guardant360 CDx Liquid Biopsy
March 09, 2023 08:00 ET
|
Sermonix Pharmaceuticals Inc.
Prospective screening of subjects for ESR1 mutations will use the Guardant360 CDx blood test for companion diagnostic developmentPhase 3 study is supported by previously presented ELAINE-1 and...
Sermonix to Present Updated Data from ELAINE-2 Clinical Trial of Lasofoxifene in Combination with Abemaciclib in Women with Locally Advanced or Metastatic ER+/HER2− Breast Cancer and an ESR1 Mutation after Progression on Prior Therapies at the 2022 ASCO Annual Meeting
May 31, 2022 15:25 ET
|
Sermonix Pharmaceuticals Inc.
COLUMBUS, Ohio, May 31, 2022 (GLOBE NEWSWIRE) -- Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company developing innovative therapeutics to specifically treat ESR1-mutated...